



**MEET OPALE CARNOT INSTITUTE  
AT ASH 2024**

*Pionnering leukemia research  
through innovation and partnering*



# Saturday, December 7



## Presenter: Jules Higué

Hall B (San Diego Convention Center) | 9:30 AM -11:00 AM PST

**Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study**

---



## Presenter: Emma Searle

Ballroom 20CD (San Diego Convention Center) | 2:00 PM-3:30 PM PST

**Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations**

---



## Presenter: Adriana Plesa

Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego) | 2:00 PM-3:30 PM PST

**FlowMRD Monitoring Combining Laip/Dfn and CD34+CD38-LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network**

---

# Saturday, December 7



**Presenter: Loic Vasseur**

Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego) |  
2:00 PM-3:30 PM PST

**Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup**

---



**Presenter: Lionel Ades**

Ballroom 20AB (San Diego Convention Center) | 4:30 PM PST

**Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study**

---



# Sunday, December 8



**Presenter: André Baruchel**

Hall B (San Diego Convention Center) | 2:00 PM-4:00 PM PST

**Plenary Introducer - Symposia: Plenary Program: Marquee Sessions**

---



**Presenter: Anne Sophie Michallet**

Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina) | 12:00 PM-1:30 PM PST

**Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group**

# Monday, December 9



**Presenter: Nicolas Boissel**

Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina) | 10:30 AM-12:00 PM PST

**Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials**